人C_1q分子对Raji、U_（937）细胞产生IL－1活性的抑制调节

为探讨Ｃ_１ｑ与免疫细胞产生的ＩＬ－１活性的关系，采用Ｒａｊｉ、Ｕ_（９３７）及对照ＭｏｌＴ_４三株培养细胞与Ｃ_１ｑ共同孵育２０ｈ后收集细胞上清，以３~Ｈ－ＴｄＲ掺入法检测ＩＬ－１活性，结果显示Ｃ_１ｑ能明显抑制Ｒａｊｉ及Ｕ_（９３７）细胞ＩＬ－１活性，对ＭｏｌＴ_４细胞无此作用，Ｆ（ａｂ＇）_２ａｎｔｉＣ_１ｑ可阻断此抑制作用；初步探讨其作用机制，推测可能Ｃ_１ｑ通过Ｃ_１ｑ受体刺激该细胞产生ＩＬ－１ＩＮＨ而抑制ＩＬ－１活性。     

曲美布汀分散片健康人体内的药代动力学及生物等效性研究曲美布汀分散片健康人体内的药代动力学及生物等效性研究

目的建立人血浆中曲美布汀的HPLC-ESI-MS测定法,研究曲美布汀在正常人体内的药代动力学行为,评价其两种制剂的生物等效性。方法血浆样品经碱化以环己烷提取,进行HPLC-ESI-MS分析,内标为西布曲明,检测离子为_m/z 388(曲美布汀)、_m/z 280(内标),裂解电压为50 V。20名健康志愿者交叉口服供试片和参比片,剂量均为100 mg。结果受试制剂及参比制剂的曲美布汀消除半衰期分别为(9.2±2.3) h和(9.2±2.8) h,达峰时间分别为(0.9±0.4) h和(1.0±0.3) h,峰浓度分别为(41±20) μg·L^-1和(40±20) μg·L^-1。以AUC_0-24h计算的受试制剂的相对生物利用度为(97±13)%。结论本法灵敏、准确、简便。统计学结果表明两种制剂生物等效。     

高效液相色谱法测定人血浆中那格列奈的含量

目的:建立高效液相色谱法测定人血浆中那格列奈含量。方法:使用固相C18提取柱,将那格列奈和双氯芬酸钠(内标)从血浆中提取,在ODS 5μm,4.6mm×150mm柱上,以流动相0.05 mol·L-1磷酸二氢钾溶液-乙腈(16:10;用1 mol·L-1氢氧化钠溶液调节pH 6.3)进行分离,流速1 mL·min-1,210nm波长检测。结果:血药浓度线性范围0.05-20μg·mL-1(r=0.9996),血浆中最低检测浓度0.05 μg·mL-1,萃取回收率在82.4％-92.2％,相对回收率98.4％-99.7％,日内及日间RSD分别为4.3％-8.2％和4.0％-8.6％。结论:本法简便、准确,精密度高,重现性好,可应用于那格列奈人体药代动力学研究和生物等效性研究。     

在药事管理中推行信息标准化体系

目的在药事管理中推行信息标准化体系,提高医院的药事信息管理水平.方法通过建立一系列涵盖药事管理各个方面的、统一的信息标准,制定标准化的业务流程和监督保障措施,使医院的药事信息形成规范化、标准化的信息流.结果与结论用临床药学、现代物流管理、数据仓库等方面的知识作指导,合理地利用这些标准化的信息,充分发挥信息化的优势,提高医院的药事信息管理水平.     

DNA聚合酶Y家族在跨损伤复制中的作用

普通的DNA聚合酶可以对正常的DNA完成复制,但是当DNA发生损伤,损伤位置就会成为DNA复制的阻滞点,普通的DNA聚合酶就无法完成基因组的复制。为了应对这种情况,生物体内还拥有另一类DNA聚合酶:聚合酶Y家族,又被称为跨损伤复制(TLS)聚合酶,它们的主要功能就是跨越损伤位点,完成基因组复制,解救濒死细胞。本文主要对Y家族聚合酶的结构特点、功能效应、作用机制等方面做一综述。     

置信区间法用于线性药代动力学特征评价

目前有多种评价线性药代动力学的方法,需要对线性动力学特征评价方法标准化、规范化。置信区间法综合考虑统计学知识与临床实践经验,将变异纳入考察范围,更符合药代动力学研究的要求。本文推荐用置信区间法评价药物线性动力学特征,有助于今后线性评价的标准化。     

慢性乙型肝炎恩替卡韦治疗过程中病毒动力学特点分析

Objective To analyze the viral dynamics and clinical significance during the antiviral treatment by a mathematical model.Methods Six chronic hepatitis B patients were evaluated with a kinetic model(Neumann model)during dose of 0.5 mg/d oral entecavir.Blood samples were drawn for HBV DNA measurement at week 0,2,4,12,24.Non-linear modeling was used to fit individual patient data.Results The median effectiveness in blocking viral production was 99.970%(n=6).The median half-life of viral turn-over was 1.6 d(n=6).The median half-life of infected hepatocytes was 21.3 d(n=5).Compared with the other patients,the c(virions are cleared at a rate)、ε(effectiveness)、δ(infected cell are lost at a rate)value of one patient(eg.6)were all lower and the half-life of virus and infected cells were higher,and eg.6 developed viral break-through after 38 weeks of follow-up.Conclusions Viral load decay showed a biphasic pattern during entecavir therapy which can be described with a mathematical model.The model relates processes of viral infection and replication as well as drug efficacy to model parameters.It indicates the prediction of bio-mathematical model during antiviral treatment.     

慢性乙型肝炎恩替卡韦治疗过程中病毒动力学特点分析

Objective To analyze the viral dynamics and clinical significance during the antiviral treatment by a mathematical model.Methods Six chronic hepatitis B patients were evaluated with a kinetic model(Neumann model)during dose of 0.5 mg/d oral entecavir.Blood samples were drawn for HBV DNA measurement at week 0,2,4,12,24.Non-linear modeling was used to fit individual patient data.Results The median effectiveness in blocking viral production was 99.970%(n=6).The median half-life of viral turn-over was 1.6 d(n=6).The median half-life of infected hepatocytes was 21.3 d(n=5).Compared with the other patients,the c(virions are cleared at a rate)、ε(effectiveness)、δ(infected cell are lost at a rate)value of one patient(eg.6)were all lower and the half-life of virus and infected cells were higher,and eg.6 developed viral break-through after 38 weeks of follow-up.Conclusions Viral load decay showed a biphasic pattern during entecavir therapy which can be described with a mathematical model.The model relates processes of viral infection and replication as well as drug efficacy to model parameters.It indicates the prediction of bio-mathematical model during antiviral treatment.     

醋酸环丙孕酮／炔雌醇复方片剂在人体的药代动力学

目的建立人血浆中醋酸环丙孕酮的HPLC—ESI—MS测定方法和丹酰氯衍生化血浆中炔雌醇的HPLC—APCI—MS测定方法,测定女性志愿者口服复方醋酸环丙孕酮片1片后的药代动力学参数,并对受试制剂和参比制剂的生物等效性进行评价。方法血浆样品中的炔雌醇以乙酸乙酯提取后,与丹酰氯发生衍生化反应,进行HPLC—APCI—MS分析,流动相为10mmol·L-1乙酸铵缓冲液（1％甲酸）-甲醇（3：97）。检测离子分别为m／z530．3（炔雌醇的丹酰氯衍生物）、m／z404．3（内标,对羟基联苯的丹酰氯衍生物1。结果在10．43～625．8Pg·ml-1范同内炔雌醇的丹酰氯衍生物与内标的丹酰氯衍生物峰面积比值与浓度呈良好的线性关系,最低定量限为10．43pg·ml-1结论本实验建立的分析方法灵敏、准确、简便,且统计学结果表明两种制剂生物等效。